僵人综合征2例报告并文献分析
童伟芳1 徐鸣明2 汪锡金1
1.同济大学附属同济医院神经内科,上海 200065; 2.上海交通大学医学院附属新华医院神经内科,上海 200092
Stiff-person syndrome: a report of two cases and literatures analysis
TONG Weifang1 XU Mingming2 WANG Xijin1
1.Department of Neurology, Tongji Hospital of Tongji University, Shanghai 200065, China; 2.Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University of Medicine, Shanghai 200092, China
摘要 僵人综合征(SPS)主要临床表现为波动性、进行性躯干和近端肢体的僵硬,伴痛性痉挛。随着病程进展,SPS患者易出现永久性骨骼异常,最终导致无法行走和残疾。但大多数患者早期可通过药物治疗得到改善。因此,早期诊断、早期治疗对预防或延缓该疾病的进展至关重要。但SPS临床表现复杂多变,给医务工作者带来了巨大的挑战。因此,医务人员需进一步加强相关理论知识的学习,提高对该病的认识。本文报道了2023年在同济大学附属同济医院就诊的2例SPS患者的病历资料,其中1例是以惊吓为诱因且合并桥本甲状腺炎的SPS患者,另1例为合并胸腺瘤的SPS患者。通过探讨该2例特殊SPS的临床特点,有助于提高医务工作者早期识别和诊断,减少误诊、误治。
关键词 :
僵人综合征 ,
临床症状 ,
桥本甲状腺炎 ,
胸腺瘤
Abstract :Stiff-person syndrome (SPS) is characterized by fluctuating, progressive stiffness of the trunk and proximal limbs, accompanied by painful spasticity. With the progression of the disease, SPS patients are prone to permanent skeletal abnormalities, eventually leading to inability to walk and disability. However, most patients can be improved by medical treatment in the early stage. Therefore, early diagnosis and treatment are essential to prevent or delay the progression of the disease. However, the clinical manifestations of SPS are complex and variable, which brings great challenges to medical workers. Therefore, doctors need to further strengthen the study of relevant theoretical knowledge and improve the understanding of this disease. This paper reports the medical records of two cases with SPS treated in Tongji Hospital of Tongji University in 2023. Among them, one was SPS patient with Hashimoto thyroiditis, and the other was SPS patient with thymoma. By discussing the clinical characteristics of the two special SPS cases, it is helpful to improve the early recognition and diagnosis of doctor and reduce misdiagnosis and mistreatment.
Key words :
Stiff-person syndrome
Clinical symptoms
Hashimoto thyroiditis
Thymoma
基金资助: 国家自然科学基金面上项目(82271227);国家重点研发计划项目(2022YFF1202804);山东省重点研发计划项目(2020CXGC011301)。
通讯作者:
汪锡金(1971-),男,博士,教授;研究方向:运动障碍相关疾病的临床与机制研究。
作者简介 : 童伟芳(1991-),女,博士;研究方向:运动障碍相关疾病的临床与机制研究。
[1] Graus F,Saiz A,Dalmau J. Gad Antibodies in Neurological Disorders-Insights and Challenges [J]. Nat Rev Neurol,2020, 16(7):353-365. [2] Dalakas MC. Therapies in Stiff-Person Syndrome:Advances and Future Prospects Based on Disease Pathophysiology [J]. Neurol Neuroimmunol Neuroinflamm,2023,10(3):e200109. [3] Meinck HM,Thompson PD. Stiff Man Syndrome and Related Conditions [J]. Mov Disord,2002,17(5):853-866. [4] Baizabal-Carvallo JF,Jankovic J. Stiff-Person Syndrome:Insights into a Complex Autoimmune Disorder [J]. J Neurol Neu- rosurg Psychiatry,2015,86(8):840-848. [5] Tsiortou P,Alexopoulos H, Dalakas MC. Gad Antibody- Spe- ctrum Disorders:Progress in Clinical Phenotypes,Immuno- pathogenesis and Therapeutic Interventions [J]. Ther Adv Neurol Disord,2021,14:17562864211003486. [6] Dalakas MC. Stiff-Person Syndrome and Gad Antibody-Spectrum Disorders:Gabaergic Neuronal Excitability,Immun-opathogenesis and Update on Antibody Therapies [J]. Neurotherapeutics,2022,19(3):832-847. [7] Martinez-Hernandez E,Ari?觡o H, McKeon A,et al. Clinical and Immunologic Investigations in Patients with Stiff- Person Spectrum Disorder [J]. JAMA Neurol,2016,73(6):714-720. [8] Balint B,Bhatia KP. Stiff Person Syndrome and Other Immune-Mediated Movement Disorders - New Insights [J] Curr Opin Neurol,2016,29(4):496-506. [9] Dalakas MC,Fujii M,Li M,et al. The Clinical Spectrum of Anti-Gad Antibody-Positive Patients with Stiff-Person Syndrome [J] Neurol,2000,55(10):1531-1535. [10] Dalakas MC,Li M,Fujii M. Stiff Person Syndrome:Quantifi- cation,Specificity,and Intrathecal Synthesis of Gad65 Antibodies [J] Neurology,2001,57(5):780-784. [11] Levy LM,Dalakas MC,Floeter MK. The Stiff-Person Syndrome:An Autoimmune Disorder Affecting Neurotransmission of Gamma-Aminobutyric Acid [J]. Ann Intern Med,1999,131(7):522-530. [12] Hac NE,Murphy OC,Butala AA,et al. Cerebellar Ataxia,and Parkinsonism in a Patient with Anti-Gad65-Associated Stiff Person Syndrome Spectrum Disorder [J]. J Neuroophthalmol,2023,43(2):273-276. [13] Strippel C,Herrera-Rivero M,Wendorff M,et al. A Genome- Wide Association Study in Autoimmune Neurological Syndromes with Anti-Gad65 Autoantibodies [J]. Brain,2023, 146(3):977-990. [14] Madlener M,Strippel C,Thaler FS,et al. Glutamic Acid Decarboxylase Antibody-Associated Neurological Syndro- mes:Clinical and Antibody Characteristics and Therapy Response [J] J Neurol Sci,2023,445:120540. [15] El-Abassi R, Soliman MY,Villemarette-Pittman N,et al. Sps: Understanding the Complexity [J]. J Neurol Sci,2019,404:137-149. [16] Wessig C,Klein R,Schneider MF,et al. Neuropathology and Binding Studies in Anti-Amphiphysin-Associated Stiff- Person Syndrome [J]. Neurol,2003,61(2):195-198. [17] Rakocevic G,Alexopoulos H,Dalakas MC. Quantitative Cli- nical and Autoimmune Assessments in Stiff Person Syndrome:Evidence for a Progressive Disorder [J]. BMC Neurol,2019,19(1):1. [18] Muranova A and Shanina E. Stiff Person Syndrome,in Statpearls [Internet]. 2023,StatPearls Publishing. [19] 李澎,尹又,庄建华.僵人综合征的研究进展[J].中国神经精神疾病杂志,2016,42(9):569-571. [20] Galli JR,Austin SD,Greenlee JE,et al. Stiff Person Syndrome with Anti-Gad65 Antibodies within the National Vet- erans Affairs Health Administration [J]. Muscle Nerve,2018, 58(6):801-804. [21] Yi J,Dalakas MC. Long-Term Effectiveness of Ivig Maintenance Therapy in 36 Patients with Gad Antibody-Positive Stiff-Person Syndrome [J]. Neurol Neuroimmunol Neuroinflamm,2022,9(5):e200011. [22] Chan CK,Maldonado DA,Wang YJ,et al. Cognitive and Mood Profiles among Patients with Stiff Person Syndrome Spectrum Disorders [J]. Fronti Neurol,2022,13:865462. [23] Jaime-Pérez JC,Meléndez-Flores JD,Ramos-Dávila EM,et al. Hematopoietic Stem Cell Transplantation for Uncommon Immune-Mediated Neurological Disorders:A Literature Review [J]. Cytotherapy,2022,24(7):676-685. [24] Kass-Iliyya L,Snowden JA,Thorpe A,et al. Autologous Hae- matopoietic Stem Cell Transplantation for Refractory Stiff- Person Syndrome:The Uk Experience [J]. J Neurol,2021, 268(1):265-275. [25] Burt RK,Balabanov R,Han X,et al. Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder:A Clinical Trial [J]. Neurol,2021,96(6):e817- e830. [26] Dalakas MC. Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome:Should There Be More to Come?[J].Neurology,2021, 96(6):239-240.
[1]
李孟晗1* 宋仁凤2* 姜久志3 刘梦友4 许斌5 朴明姬6 崔建春7. 人工智能辅助临床-超声-舌象多组学联合诊断非哺乳期乳腺炎的研究进展 [J]. 中国医药导报, 2023, 20(34): 57-60,73.
[2]
孙晶1 李庆伟1 汪金宇1 杨锐1 马建1 张福利2. 张福利教授基于太阴-阳明理论治疗桥本甲状腺炎经验 [J]. 中国医药导报, 2023, 20(27): 133-136.
[3]
戴玉 杨静 雷冬雪 刘华影. 揿针疗法对冠心病经皮冠脉介入术后不稳定型心绞痛气虚血瘀证患者临床症状及炎症因子的影响 [J]. 中国医药导报, 2023, 20(23): 85-89.
[4]
贾伟1 王芬1 王灿1 陆雅婷2 郭文露1 李晓蝶1 朱德发1. 参芪十一味颗粒联合左甲状腺素钠片治疗脾肾阳虚型桥本甲状腺炎的效果 [J]. 中国医药导报, 2023, 20(15): 77-81.
[5]
桥本甲状腺炎中西医结合诊疗北京专家共识(2021,北京). 桥本甲状腺炎中西医结合诊疗北京专家共识(2021,北京) [J]. 中国医药导报, 2022, 19(34): 4-7.
[6]
张宸 李景 尚菊菊. 升降汤合半夏厚朴汤加减治疗肝郁脾虚型桥本甲状腺炎亚临床甲减的临床效果 [J]. 中国医药导报, 2022, 19(33): 71-74.
[7]
谢凯丽1 王二晓2 梁娟1▲. 趣味化健康教育对过敏性紫癜患儿负性情绪及临床症状改善效果的影响 [J]. 中国医药导报, 2022, 19(31): 194-封三.
[8]
徐首静1 祁烁2 商建伟3 户蕊3 陈晓珩3 姚思淼1 丁治国2. 甲状腺功能正常的桥本甲状腺炎患者临床症状及证型分布规律 [J]. 中国医药导报, 2022, 19(29): 134-138.
[9]
弋曼 梁娟 何金孝 李晶晶 朱亚琼▲. 循证护理应用于百日咳患儿临床效果及价值研究 [J]. 中国医药导报, 2022, 19(21): 169-172.
[10]
耿文倩 祁烁 陈晓珩 李哲 李会龙 刘美君 葛亚雪 丁治国. 硒与桥本甲状腺炎的相关性研究进展 [J]. 中国医药导报, 2022, 19(10): 55-58.
[11]
赵雪茹1 陈继东2 马利1. 近四十年中医药治疗桥本甲状腺炎的文献计量学分析 [J]. 中国医药导报, 2021, 18(14): 22-26.
[12]
付金香1 祁烁2 陈晓珩2 李会龙2 黄盛1 李心爱1 张磊1 丁治国2. 丁治国教授治疗桥本甲状腺炎合并甲状腺结节案例一则 [J]. 中国医药导报, 2020, 17(7): 120-123.
[13]
杨亮亮 庞瑞. 中药联合针灸治疗术后胃瘫综合征的临床效果 [J]. 中国医药导报, 2020, 17(3): 147-150.
[14]
白春林 何涛 肖莉 王韧 张天佑. 金水宝胶囊联合左甲状腺素片治疗桥本甲状腺炎的效果及对过氧化物酶抗体和炎症因子的影响 [J]. 中国医药导报, 2020, 17(22): 148-151.
[15]
尹谢添1,2,3 赵诗超4 向楠1,3 周广文3,5 曾明星3,6. 系统性红斑狼疮患者伴发甲状腺疾病的临床分析 [J]. 中国医药导报, 2020, 17(14): 131-134,149.